HONG KONG (Reuters) – When Hong Kong unveiled plans last year to encourage biotech companies to list in the city by loosening listing rules, the financial industry and investors cheered.
READ Hong Kong scrambles for talent in battle for Nasdaq's biotech crown On Reuters